Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

185.92 -3.47 (-1.83%)

Delayed Quote Updated: 12:19 PM EST, Nov 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 Next >

AstraZeneca (NYSE:AZN) Stands Out for Dividend Quality and Sustainable Payout ↗

November 05, 2026

Via Chartmill

AstraZeneca: 3 Key Takeaways for Long-Term Investors ↗

November 01, 2026

Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.

Via The Motley Fool

Topics Earnings Intellectual Property

AstraZeneca (AZN) Q3 2026 Earnings Call Transcript ↗

October 31, 2026

Oncology and rare disease momentum offset cardiovascular headwinds.

Via The Motley Fool

Topics Earnings

AstraZeneca Q3 Earnings Call Highlights ↗

October 30, 2026

AstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology,...

Via MarketBeat

Topics ETFs Earnings

AstraZeneca (NYSE:AZN) Passes the Caviar Cruise Quality Screen with Strong Profitability and Growth ↗

April 24, 2026

Via Chartmill

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update ↗

October 26, 2026

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the...

Via MarketBeat

Topics ETFs

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

This beaten-down biotech has a better story than its stock chart suggests.

Via The Motley Fool

AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗

October 12, 2026

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research...

Via MarketBeat

Topics ETFs

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Via The Motley Fool

2 Growth Stocks to Buy in October ↗

October 08, 2026

Grail and Veeva Systems could be well insulated from near-term headwinds.

Via The Motley Fool

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Analysts think Alnylam could rebound strongly over the next 12 months.

Via The Motley Fool

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗

September 13, 2026

Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting...

Via MarketBeat

Topics ETFs

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Via The Motley Fool

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Via The Motley Fool

Topics Intellectual Property

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Via The Motley Fool

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

Via The Motley Fool

Astrazeneca Q2 Earnings Call Highlights ↗

July 27, 2026

Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per...

Via MarketBeat

Topics ETFs Earnings

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage ↗

July 11, 2026

Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned...

Via MarketBeat

Topics Artificial Intelligence Climate Change ETFs

IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗

July 02, 2026

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

Via The Motley Fool

Topics ETFs

IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗

June 10, 2026

When buying international ETFs, owning more stocks in more countries might be a better bet.

Via The Motley Fool

Topics ETFs

Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗

May 23, 2026

Panama-based Copa Holdings operates a major airline network across the Americas, serving both passenger and cargo markets.

Via The Motley Fool

Topics Regulatory Compliance

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Via The Motley Fool

Topics Artificial Intelligence ETFs

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗

May 18, 2026

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

Via MarketBeat

Topics Credit Cards ETFs Economy

M&G Shaved 2.4% of Methanex After a Near-Doubling ↗

May 17, 2026

Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

This Low-Cost ETF Holds Almost 8,800 Stocks Across Both Developed and Emerging Markets. Here's Why It's a Compelling Long-Term Core Holding ↗

May 07, 2026

If you're looking for diversification and value, here's a good ETF to check out.

Via The Motley Fool

Topics ETFs

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

May 02, 2026

Via MarketBeat

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Pictet Loads Up MercadoLibre With 3,500 Shares Worth $6.8 Million ↗

April 14, 2026

MercadoLibre powers e-commerce, payments, and logistics for millions in Latin America with its integrated digital platform.

Via The Motley Fool

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.